VanEck Pharmaceutical ETF (NASDAQ:PPH) Sees Strong Trading Volume – Still a Buy?

VanEck Pharmaceutical ETF (NASDAQ:PPH) shares saw unusually-high trading volume on Friday . Approximately 178,773 shares were traded during mid-day trading, an increase of 44% from the previous session’s volume of 123,941 shares.The stock last traded at $86.75 and had previously closed at $86.34.

VanEck Pharmaceutical ETF Trading Up 0.5 %

The stock has a market capitalization of $641.16 million, a PE ratio of 21.04 and a beta of 0.72. The firm has a 50 day moving average of $88.98 and a two-hundred day moving average of $92.56.

VanEck Pharmaceutical ETF Increases Dividend

The firm also recently announced a dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 27th were given a dividend of $0.411 per share. The ex-dividend date was Friday, December 27th. This is a boost from VanEck Pharmaceutical ETF’s previous dividend of $0.36.

Institutional Trading of VanEck Pharmaceutical ETF

Several institutional investors and hedge funds have recently made changes to their positions in PPH. FMR LLC increased its stake in shares of VanEck Pharmaceutical ETF by 12.5% during the 3rd quarter. FMR LLC now owns 1,905 shares of the company’s stock valued at $181,000 after acquiring an additional 212 shares during the last quarter. Edge Financial Advisors LLC acquired a new position in shares of VanEck Pharmaceutical ETF during the 3rd quarter valued at $263,000. Harbour Investments Inc. boosted its position in VanEck Pharmaceutical ETF by 16.6% during the 3rd quarter. Harbour Investments Inc. now owns 3,425 shares of the company’s stock worth $325,000 after purchasing an additional 488 shares during the period. Townsquare Capital LLC increased its holdings in VanEck Pharmaceutical ETF by 3.8% in the 3rd quarter. Townsquare Capital LLC now owns 3,519 shares of the company’s stock valued at $334,000 after purchasing an additional 130 shares in the last quarter. Finally, Assetmark Inc. increased its holdings in VanEck Pharmaceutical ETF by 5.8% in the 3rd quarter. Assetmark Inc. now owns 6,491 shares of the company’s stock valued at $617,000 after purchasing an additional 354 shares in the last quarter.

About VanEck Pharmaceutical ETF

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.